Article Text

Download PDFPDF
Large and middle hepatitis B surface antigen: the lower the better?

Statistics from


  • Contributors HHL and TCT drafted the manuscript. JHK did the critical review of the manuscript.

  • Funding This work was supported by the grants from the Ministry of Science and Technology, Executive Yuan, Taiwan (MOST 105-2314-B-303-008).

  • Competing interests JHK is the consultant for Abbvie, Bristol-Myers Squibb and Gilead Sciences; on speaker’s bureau for Abbvie, Bristol-Myers Squibb, Gilead Sciences and Merck.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.